Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 Articles
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Members & Subscribers
    • Benefits for CMA Members
    • CPD Credits for Members
    • Subscribe to CMAJ Print
    • Subscription Prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
News

The all-clear signal for rare heart arrhythmias

Stephen Strauss
CMAJ March 06, 2012 184 (4) E213-E214; DOI: https://doi.org/10.1503/cmaj.109-4104
Stephen Strauss
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Responses
  • Metrics
  • PDF
Loading

Discovering a gene for a rare but often fatal arrhythmia has allowed doctors in Newfoundland and Labrador to prescribe a treatment before any symptoms arise and physicians in northern British Columbia to differentiate symptoms associated with a bad lifestyle from a genetic predisposition for another heart condition.

But has that affected the practice of coronary medicine within the broader Canadian population?

To answer that, consider the case of Grace Verbeek, who finished seventh in the semifinals of the 800-metre competition while representing Canada at the 1984 Summer Olympics. In 2007, when she was 48, Verbeek recalls arriving at a track facility in Ottawa, Ontario, where she coached. Then her memory runs dry.

She now characterizes it as a day on which “all my little angels lined-up.” A coaching colleague noticed her acting strangely and summoned several people to administer cardiopulmonary resuscitation. A cardiologist who was at the facility watching his son play soccer surmised that Verbeek was in cardiac arrest and contacted paramedics.

So almost by chance Verbeek survived. The following day, a battery of tests at the University of Ottawa Heart Institute (OHI) revealed nothing wrong with her heart. So genetic tests were conducted on Verbeek and relatives in Holland.

The tests came back with a genetic fingerprint which predisposes carriers to arrhythmogenic right ventricular cardiomyopathy (ARVC).

Unlike Newfoundlanders or members of the Gitxsan First Nation, the gene had left no discernible mark in Verbeek family records or its oral history. “My mother has done the family tree and has been going through family history for years and there is no record of people suddenly keeling over,” she says.

Verbeek now takes beta blockers, has had a defibrillator implanted and has adjusted her exercise regimen to avoid sudden spurts in heart rhythm. Other family members who have been shown to be carriers are either being treated or are being closely watched. More distant relatives in Holland have been advised to be tested.

Figure

Among therapeutic preventive measures for people with rare heart arrhythmias is the insertion of implantable defibrillators.

Image courtesy of © 2012 Thinkstock

Such cases have helped to provide “much greater clarity” to clinicians “in circumstances where we have good correlation between mutations and a clinical syndrome,” says Dr. Robert Gow, a pediatric cardiologist at the Children’s Hospital of Eastern Ontario in Ottawa.

But the long-term effect on carriers may be both beneficial and problematic.

“We know that the penetrance in a family is not 100%,” says Dr. Michael Gollob, a cardiologist at OHI. “You can carry the bad gene, but you can look perfectly normal your whole life. But your children may not look perfectly normal.”

Early identification of a carrier, in some instances, has allowed clinicians to prescribe therapeutic preventive measures, such as medications or defibrillators.

As importantly, argues Dr. Robert Roberts, president, CEO and chief scientific officer of OHI, and one of the original researchers who hunted for the Newfoundland ARVC gene, the findings of a genetic test can give some people an “all-clear” signal by identifying that they aren’t carriers.

That’s profound, he argues. “If children carry a gene which has been associated with the possibility of a disease or carry an unknown variation for that disease typically they will be followed by echocardiograms not just for every three to five years but probably for the rest of their lives. However, if you do genetic testing and find that half don’t have the gene you will avoid the emotional trauma of a life-long testing, something which is both cost effective and certainly emotionally relieving.”

Is it valid, therefore, to conclude that the relative and absolute successes of heart genetics in diagnosing and treating arrhythmias presages a new clinical future for medicine?

Nobody knows, though researchers are sure more and more genetic information will be made available for doctors to try to fit into the dramatically reconfigured diagnosis and treatment models for rare arrhythmias.

“The thing about the genetic revolution that we are realizing is that it is not one pill fits all, not one test fits all,” says Alexandre Stewart, associate professor and research at OHI.

Stewart believes future research will inform physicians about which patients over age 50 are best treated with preventive medications. As well, “if you narrow down who you aren’t going to treat, you could save a lot of money.”

It might not be the genetic revolution that just a decade ago was predicted as imminent, but it lays a foundation for a bit of genetics-based personalized medicine.

Third of a three part series:

Part 1: The rhythms of the Rock (www.cmaj.ca/lookup/doi/10.1503/cmaj.109-4102).

Part 2: The heartbeat of a First Nation (www.cmaj.ca/lookup/doi/10.1503/cmaj.109-4103).

Stephen Strauss’ research was made possible in part by a $20 000 Canadian Institutes of Health Research Journalism Award.

PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 184 (4)
CMAJ
Vol. 184, Issue 4
6 Mar 2012
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The all-clear signal for rare heart arrhythmias
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The all-clear signal for rare heart arrhythmias
Stephen Strauss
CMAJ Mar 2012, 184 (4) E213-E214; DOI: 10.1503/cmaj.109-4104

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
The all-clear signal for rare heart arrhythmias
Stephen Strauss
CMAJ Mar 2012, 184 (4) E213-E214; DOI: 10.1503/cmaj.109-4104
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • What to know about Omicron XBB.1.5
  • Could a flu shot push help curb pediatric hospitalizations?
  • Stalemate: What’s holding up a new health accord?
Show more News

Similar Articles

Collections

  • Topics
    • Cardiology: arrhythmias
    • Genetics

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
  • Accessibiity
  • CMA Civility Standards
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: cmajgroup@cmaj.ca

Powered by HighWire